Yuqin News Today

Bringing Taiwan to the World and the World to Taiwan

Golidocitinib can produce lasting responses in patients with relapsed or refractory PTCL, according to a new study. Golidocitinib can produce lasting responses in patients with relapsed or refractory PTCL, according to a new study.

Relmacabtagene autoleucel continued to induce responses with acceptable tolerability in Chinese patients with relapsed or refractory mantle cell lymphoma.

This year marks the 10th anniversary of Chinese President Xi Jinping’s proposal to build a community with a shared future for mankind, the principles guiding China’s Africa policy, including sincerity, real results, amity and good faith and the Belt and Road Initiative (BRI).

The high-level official has not attended a public event in three weeks

Hangzhou Vanke Junxi Club, China by WE DESIGN by We Design

XIAMEN, April 19 (Xinhua) -- Guqin is one of the oldest musical instruments in China, with more than 3,000 years of history. A Jordanian journalist has experien

Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting - read this article along with other careers information, tips and advice on BioSpace

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in...